Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Amyloid Fibrils03:03

Amyloid Fibrils

6.3K
6.3K
Amyloid Fibrils03:03

Amyloid Fibrils

11.6K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.6K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.5K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.5K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.2K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.4K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.4K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

576
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
576

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Lung Transplantation for Pulmonary Alveolar Proteinosis - a Retrospective International Multi-Center Analysis.

The European respiratory journal·2026
Same author

[Comparative analysis of drug therapy for fibrotic interstitial lung diseases based on results of phase 3 study].

Pneumologie (Stuttgart, Germany)·2026
Same author

Advances in Sarcoidosis.

Archivos de bronconeumologia·2026
Same author

KL-6 as a Biomarker for Adult Patients with Cystic Fibrosis and the Impact of <i>MUC1</i> Genotype.

Journal of clinical medicine·2026
Same author

Olive Oil and the Impact of Gastrointestinal Adverse Events During Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: A Post-hoc Analysis of the MADIET Trial.

Archivos de bronconeumologia·2026
Same author

Radiation dose and signal-to-noise ratio in pediatric head CT: a phantom study comparing photon-counting and energy-integrating detectors.

Neuroradiology·2026

相关实验视频

Updated: Jan 15, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

906

肺 Amyloidosis 肺 Amyloidosis 肺 Amyloidosis 肺 Amyloidosis 肺 Amyloidosis 肺 Amyloidosis 肺 Amyloidosis 肺 Amyloidosis 肺

Stefano Levra1,2, Marcel Opitz3, Francesco Bonella4

  • 1Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Seminars in respiratory and critical care medicine
|October 14, 2025
PubMed
概括
此摘要是机器生成的。

氨基粉症涉及组织中的蛋白质积累,肺部参与是常见的,但通常是轻微的. 本综述涵盖了最近的分子见解,分类,肺粉样化症类型和治疗方法,强调需要提高认识和专门中心.

更多相关视频

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa
07:27

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa

Published on: July 12, 2018

5.9K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

11.3K

相关实验视频

Last Updated: Jan 15, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

906
Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa
07:27

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa

Published on: July 12, 2018

5.9K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

11.3K

科学领域:

  • 肺部医学 肺部医学
  • 罕见疾病 罕见疾病
  • 分子生物学分子生物学

背景情况:

  • 氨基粉症包括由于蛋白质沉积错误折叠而引起的罕见疾病.
  • 肺部感染很常见,但通常是轻微的,尽管存在严重的形式.
  • 了解分子机制和分类正在不断发展.

研究的目的:

  • 审查最近在粉样症分子机制和分类方面的进展.
  • 描述各种形式的肺粉样化症.
  • 概述目前肺部粉样化症的治疗策略.

主要方法:

  • 关于最近科学进展的文献评论.
  • 合成有关分子机制的信息.
  • 编制有关分类和临床表现的数据.
  • 治疗选择的总结.

主要成果:

  • 最近在了解amyloidosis分子通路方面的进展.
  • 更新了粉症的分类系统.
  • 描述各种肺部粉样化症的表现.
  • 现有和新兴治疗方法的概述.

结论:

  • 提高对粉样症的医疗意识至关重要.
  • 建立推中心网络对于患者管理至关重要.
  • 及时诊断和获得专业护理可以改善肺部粉样症的结果.